A Study of AMG 732 in Healthy Participants and Participants With Thyroid Eye Disease
← catalyst calendarNCT06401044 · readout in 140 d
Sponsored by Amgen (industry) · AMGN — their whole pipeline →.
Phase
Phase 1/2
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · Double · Treatment
Enrollment
94actual
Sites
44
Countries
Australia, Canada, France +9
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-05-30 | actual | When the study began enrolling |
| Primary completion | 2027-01-06 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-12-24 | estimated | The whole study's end, after follow-up |
| First posted | 2024-05-06 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-10 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Thyroid Eye Disease
Interventions
- Drug: AMG 732
- Other: Placebo
Primary outcomes
what the primary-completion date above is the date OFPart A: Number of Participants With Treatment-emergent Adverse Events
measured Day 1 through Week 36 (End of Study)
Part B: Change from Baseline in Proptosis Measurement by an Exophthalmometer in the Study Eye
measured Baseline to End of Treatment (EoT) (approximately 6 Months)
Permalink · AMGN's whole pipeline · Catalyst calendar · Every registered study · What changed